Publications by authors named "Shirin Varmazyar"
Background: Preclinical research has identified the mechanisms via which bacteria influence cancer treatment outcomes. Clinical studies have demonstrated the potential to modify the microbiome in cancer treatment. Herein, we systematically analyze how gut microorganisms interact with chemotherapy and immune checkpoint inhibitors, specifically focusing on how gut bacteria affect the pharmacokinetics and pharmacodynamics of cancer treatment.
View Article and Find Full Text PDFArticle Synopsis
- Cellular lipid membranes act as barriers against viral infections and can also serve as interaction points for viruses, with lipid rafts playing a crucial role in the viral life cycle.
- The enzyme PCSK9 is important for maintaining cholesterol levels and has become a target for therapeutic interventions, such as FDA-approved inhibitors like inclisiran and evolocumab, which lower LDL cholesterol levels.
- Recent studies suggest that inhibiting PCSK9 may not only help with cholesterol management in HIV-positive patients but could also have protective effects against various viruses, including hepatitis C, dengue, and possibly SARS-CoV-2, highlighting its potential as a novel treatment approach.